BUZZ - Citi upgrades XPO rating to "Buy" due to increased market share and strong pricing power
路透社2026/10/07 12:27October 7 - Citigroup has upgraded logistics company XPO (XPO.N) from “Neutral” to “Buy,” and raised its target price to $224, indicating an upside potential of about 22% from the previous trading day’s closing price. The brokerage stated that the upgrade was made after the stock declined from the $230 range to its current level of $183 per share. It also added that the recent broad pullback in the transportation sector has created a "more favorable risk-reward setup" for the third-quarter earnings season. Citigroup noted, "Notably, XPO has been particularly optimistic about its Q3 earnings, expecting an opportunity to gain market share and maintain pricing power." Among 26 brokerages, 19 rate the stock "Buy" or above, 6 rate it "Hold," and 1 rates it "Sell"; the median target price is $238 according to data compiled by the London Stock Exchange Group (LSEG). As of yesterday’s close, the stock had risen 35% year-to-date.
October 7 - ** Citigroup upgraded logistics company XPO (XPO.N) from “Neutral” to “Buy”; the target price was raised to $224, representing about 22% upside from the previous trading day’s closing price
** The brokerage stated that, given the stock has fallen from the $230 range to the current $183 per share, it has upgraded the rating
** It added that the recent broad pullback in the transportation sector has created a “more favorable risk/reward profile” for the third-quarter earnings season
** Citigroup stated: “It is noteworthy that XPO has expressed particular optimism about its third-quarter results, expecting opportunities to gain market share and maintain pricing advantages”
** Out of 26 brokerages, 19 rate it “Buy” or higher, 6 rate it “Hold”, and 1 rates it “Sell”; the median target price is $238 — according to data compiled by London Stock Exchange Group (LSEG)
** As of yesterday’s close, the stock is up 35% year-to-date
(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation texts and provides them for reader convenience only. Reuters accepts no liability whatsoever for any damage or loss resulting from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises
On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.
Antofagasta’s Centinela strike adds copper supply risk
Elon Musk personally defines Terafab: TSMC can at most "sublease a portion," operation is out of the question.
Musk clarified that Terafab will be independently constructed and operated, with TSMC possibly subleasing part of the site; Intel will be involved in technology development and will supply Tesla and SpaceX AI.
